| Literature DB >> 31057338 |
Naomi C Brownstein1,2,3, Thomas A Louis4, Anthony O'Hagan5, Jane Pendergast6.
Abstract
This article resulted from our participation in the session on the "role of expert opinion and judgment in statistical inference" at the October 2017 ASA Symposium on Statistical Inference. We present a strong, unified statement on roles of expert judgment in statistics with processes for obtaining input, whether from a Bayesian or frequentist perspective. Topics include the role of subjectivity in the cycle of scientific inference and decisions, followed by a clinical trial and a greenhouse gas emissions case study that illustrate the role of judgments and the importance of basing them on objective information and a comprehensive uncertainty assessment. We close with a call for increased proactivity and involvement of statisticians in study conceptualization, design, conduct, analysis, and communication.Entities:
Keywords: Bayesian paradigm; Clinical trials; Collaboration; Elicitation; Scientific method; Subjectivity
Year: 2019 PMID: 31057338 PMCID: PMC6474725 DOI: 10.1080/00031305.2018.1529623
Source DB: PubMed Journal: Am Stat ISSN: 0003-1305 Impact factor: 8.710
Fig. 1The cycles of inference and decision.
a weighted average of stratum-specific log hazard ratios, each comparing BiV versus RiV pacing; PP0 posterior probability that the study objective has been met, PRR posterior probability the study objective has not been met.
| Decision boundaries | |||||
|---|---|---|---|---|---|
| Conclude objective is met and stop study early | Conclude that sample size is sufficient to continue | Determine that sample size is insufficient but elect not to increase sample size | Conclude that sample size must be increased in increments of 175 | Stop study for safety | |
| First Interim Analysis | P ( | ||||
| Sample Size Re-estimation Phase | N/A | N/A | |||
| Second Interim Analysis | If neither the outcome in column 2 nor the outcome in column 6 occurs, then the study will continue with the current sample size. | P ( | |||
NOTE: See Curtis et al. (2013) for details.
Fig. 2Elicited priors for the five elicitees. The red vertical line at P0 is the “best guess” two-year incidence of TOXO or death under placebo. The smoothed densities are for two-year TOXO or death incidence under pyrimethamine, conditional on the placebo rate.
Fig. 3Posterior probability of benefit (hazard ratio ) and harm (hazard ratio > 1.0) for the mixture prior (blue lines) and for monitoring based on the partial likelihood (black lines), which is equivalent to using a flat (improper) prior. Monitoring was at calendar dates (15 Jan 1991, 31 Jul 1991, 31 Dec 1991, 30 Mar 1992) with the X-axis indicating the cumulative number of toxoplasmosis or death events from the combined arms.